GINA 2024 Asthma Update: Revised Recommendations on …
Jun 28, 2024 · The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more.
Updated 2023 GOLD Report Revises COPD Definitions and …
Jan 20, 2023 · The 2023 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) — “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” (COPD) 1 — details “an expanded range of therapies for COPD that now can be considered to improve mortality,” according to Gerard J. Criner, MD, FACP, FACCP, an author of the 2023 GOLD ...
2024 GOLD Report Reflects New Research on COPD Management
Dec 8, 2023 · Shifts in Thinking About COPD. Although many changes in the 2024 report reflect new research released from January 2022 to July 2023 (148 new references in total), the updated report does more than just incorporate this new research, said Dr Vogelmeier. The new “consolidated” report continues to refine the definition of COPD and pre-COPD ...
Paxlovid vs Azvudine: Nirmatrelvir/Ritonavir Superior for COVID-19 ...
2 days ago · November 11, 2024. Although patients with COVID-19 treated with nirmatrelvir/ritonavir had more severe pneumonia, they also had faster viral clearance than those treated with azvudine. The antiviral effect of nirmatrelvir/ritonavir (Paxlovid) is significantly superior to azvudine in hospitalized patients with COVID-19 pneumonia, investigators ...
Chronic Obstructive Pulmonary Disease (COPD) - Pulmonology …
Nov 15, 2023 · Overview. Chronic obstructive pulmonary disease (COPD) refers to a group of conditions that include emphysema and chronic bronchitis and is characterized by progressive airflow limitation and tissue destruction. 1 It is associated with structural changes in the lungs due to chronic inflammation, typically caused by prolonged exposure to noxious ...
Dupilumab in COPD Linked to Lower Mortality, Better Long-Term …
November 6, 2024. Dupilumab in COPD was linked to lower risk for all-cause mortality (HR, 0.53), emergency visits (HR, 0.78), exacerbations (HR, 0.59), and pneumonia (HR, 0.65). Dupilumab was associated with a decreased risk for all-cause mortality, emergency visits, acute exacerbations (AEs), respiratory failure, and respiratory infections in ...
Long COVID Linked to Initial Disease Severity, Pre-existing COPD …
October 10, 2024. Long COVID development was associated with having COPD or OSA and having specific oxygen or ventilation requirements during the initial COVID-19 hospitalization. Development of long COVID may be influenced by severity of the initial COVID-19 infection and pre-existing respiratory conditions, according to research presented at ...
Tezspire Reduces Nasal Congestion and Polyp Size in Chronic …
2 days ago · November 11, 2024. Full results from the trial will be presented at an upcoming medical meeting. Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Tezepelumab is a human monoclonal antibody ...
Trelegy Ellipta Improves Lung Function in Patients With …
May 7, 2019 · While not considered statistically significant, Trelegy Ellipta (100/62.5/25mcg and 200/62.5/25mcg) was associated with a 13% reduction in asthma exacerbations when compared with Breo Ellipta (100/25mcg and 200/25mcg). In addition, the study investigated 2 additional doses of Trelegy: 100/31.25/25mcg and 200/31.25/25mcg; increases in trough FEV ...
Switching Between Inhalers, Both pMDI and DPI, Common in …
October 4, 2024. Inhaler preference appeared to vary by age, with pDMI used by more patients aged 75 years and older, and DPI used by more patients aged 40 to 60 years. Patients with asthma and chronic obstructive pulmonary disease (COPD) routinely switch from pressurized metered-dose inhalers (pMDIs) to dry powder inhalers (DPIs) and vice ...